Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2010-01-04 Merger & Acquisition
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933, which is typically used for merger communications. It references a presentation made available on the Novartis website related to Alcon Inc. The document length is very short (613 characters) and does not contain substantive financial data or detailed report content. Given the Rule 425 reference and the nature of the document as a presentation related to a merger or acquisition, the appropriate classification is Merger & Acquisition (MA).
2010-01-04 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing the World Health Organization's prequalification of Novartis's influenza A(H1N1) 2009 vaccines. It includes detailed product descriptions, forward-looking statements, and contact information. There are no financial statements, audit opinions, or detailed financial data presented. The document is an announcement of corporate news rather than a full financial report or regulatory certification. Form 6-K filings typically serve as periodic reports to disclose material information between annual reports (20-F or 40-F). Given the nature of the content and the form type, this filing best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2009-12-29 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces the acquisition of Corthera Inc. by Novartis, detailing the terms of the acquisition, the strategic rationale, and forward-looking statements. There are no financial statements or detailed financial performance data included. The document is an announcement of a corporate transaction (acquisition) rather than a full merger filing or tender offer statement. It does not contain quarterly or annual financial results, nor is it a regulatory certification or voting result. Given the nature of the content focusing on acquisition news and related strategic information, the most appropriate classification is a Capital/Financing Update (CAP). The document length is substantial (over 13,000 characters), indicating it is not a brief announcement or a report publication announcement. Therefore, the classification is CAP with high confidence.
2009-12-29 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of a press release announcing the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending approval of the meningococcal vaccine Menveo in the European Union. The document includes detailed information about the vaccine, its development, disease background, and regulatory status. It is not a full annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about a product approval status and related forward-looking statements. The document length is substantial (15,000 characters), and it is not merely an announcement of a report publication but a substantive disclosure. Given the nature of the filing (Form 6-K) and content, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2009-12-18 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer submitted pursuant to the Securities Exchange Act of 1934. The text includes detailed information about Novartis' oncology and non-oncology drug development pipeline, regulatory submission plans, clinical trial progress, and strategic updates. It is an investor relations release providing comprehensive updates on the company's pharmaceutical pipeline and regulatory activities. The document is not an annual or quarterly report, audit report, earnings release, or any other specific financial report type. Instead, it is a regulatory filing that provides material information to investors and the SEC about ongoing business developments and regulatory plans. Given the nature of Form 6-K filings as periodic reports of material information by foreign private issuers, and the detailed business update content, the appropriate classification is Regulatory Filings (RNS).
2009-12-10 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, a foreign private issuer, submitted to the SEC. It contains detailed clinical trial results and efficacy data for the drug Tasigna compared to Glivec in treating chronic myeloid leukemia. The document is an investor relations release presenting clinical trial outcomes and plans for regulatory filings worldwide. It is not an annual or quarterly financial report, audit report, or earnings release. It is a regulatory filing reporting material clinical trial results and corporate news. The document length is about 15,000 characters, indicating it is a substantive report rather than a brief announcement. Form 6-K filings are typically classified as Regulatory Filings (RNS) in this taxonomy, as they are miscellaneous reports by foreign private issuers that do not fit into other categories like 10-K or IR. Therefore, the appropriate classification is Regulatory Filings (RNS).
2009-12-10 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.